Regulatory momentum validates the multi-cancer blood test category the company is working to enter
BOSTON, Mass., October 8, 2026 – EarlySignal Diagnostics, Inc., developer of an AI-powered blood
test for early multi-cancer detection, participated this week in the World Clinical Biomarkers &
Companion Diagnostics Summit at the Westin Boston Seaport District, October 5–8. The meeting
convened biopharma, diagnostics, regulatory and laboratory leaders to discuss liquid biopsy,
multi-omics and AI-driven diagnostics.
EarlySignal’s attendance comes weeks after a landmark regulatory moment. On September 23, an
FDA advisory panel voted that the benefits of Grail’s Galleri multi-cancer early detection test outweigh
its risks. It was the first time a federal advisory group backed this class of test. Final FDA action is still
pending, but approval would likely open the door to broader Medicare and private insurer coverage.
“The panel’s vote is a meaningful signal that regulators are taking multi-cancer blood testing seriously,”
said Dr. Sean McCafferty, Chief Executive Officer of EarlySignal Diagnostics. “It also showed the
evidence bar clearly: performance in early-stage disease and real-world clinical benefit must be
demonstrated. That is exactly where we are focusing our validation work.”
EarlySignal’s test combines AI with methylation-based multi-omics to detect tumor-derived signals in
cell-free DNA from a single blood draw. The test is in development and clinical validation and is not yet
available for clinical use.
“We see the FDA’s engagement as a positive for the sector and for patients,” added Dr. McCafferty.
“Events like this summit give us valuable insight into the evolving regulatory and clinical landscape as
we advance our program.”
About EarlySignal Diagnostics
EarlySignal Diagnostics is developing a next-generation blood test that combines AI with genomic and
epigenomic biomarkers to detect multiple cancers before symptoms appear, when treatment is most
effective. Learn more at www.earlysignaldiagnostics.com
Media Contact
Dr. Sean McCafferty, CEO
roy@earlysignaldiagnostics.com | 617-CANCERS
68718 East Palm Canyon Drive, Suite 301-588, Cathedral City, California 92234
This test is under development and has not been cleared or approved by the FDA.
